Biophysical techniques such as NMR spectroscopy and X-ray crystallography are central to drug discovery. With their help, we can identify weak binders, characterize ligand-binding sites, and elucidate molecular interactions within ligand-protein complexes. Our proprietary fragment library, optimized for weak-affinity chromatography and NMR screening, includes about 1,300 low-molecular-weight (<220) MedChem-friendly compounds. These compounds are designed to cover diverse chemical space and are general-purpose. More than 90% of the compounds are commercially available, enabling rapid SAR generation. For crystallographic fragment screening, we have designed a specific kinase-focused fragment library in collaboration with the FragMax platform staff. The FragMax facility was explicitly designed to facilitate crystallographic fragment screening projects. Our blog post on this subject discusses the advantages of crystallographic fragment screening and details the service. Our clients are also welcome to send their own libraries for screening.
